Skip to content
Peptide research

VIP

Also known as Vasoactive Intestinal Peptide
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

A naturally occurring peptide marketed for anti-inflammatory, lung, and gut effects. Human evidence is moderate for its anti-inflammatory and lung-relaxing effects, but the neuroprotective, sleep, and gut benefits rest on animal and mechanism data. It sharply lowers blood pressure, clears within minutes, and carries a theoretical tumor-promotion concern, with scant long-term safety data. Not FDA-approved; sold as an unregulated research-grade product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino-acid signaling molecule found throughout the brain, gut, lungs, and immune system. Discovered in 1970, it serves as a neurotransmitter, blood vessel relaxer, immune regulator, and master synchronizer of your body's internal clock. The synthetic form, Aviptadil, has been studied for pulmonary hypertension and severe COVID-19 respiratory failure, and received FDA Fast Track Designation, though it has not yet been approved.

How it works in the body

Vasoactive Intestinal Peptide binds to VPAC1 and VPAC2 receptors (G-protein coupled) found throughout the nervous system, gut, and immune system. It activates adenylyl cyclase, raising cAMP levels. This relaxes smooth muscle (bronchodilation, vasodilation), reduces inflammation, promotes neuroprotection, and regulates circadian rhythms.

Research overview

VIP is one of the most multi-functional signaling molecules in the body, with over 10,000 published studies spanning five decades. It reduces inflammation by suppressing inflammatory signals (TNF-alpha, IL-6) while promoting anti-inflammatory ones (IL-10), and it trains immune cells toward tolerance — a landmark Nature Medicine study showed it prevented experimental arthritis. In the lungs, VIP relaxes blood vessels and is deficient in patients with pulmonary hypertension; inhaled VIP improved lung function in clinical studies. For neuroprotection, VIP stimulates the release of brain-protective factors relevant to Alzheimer's and Parkinson's disease. During COVID-19, Aviptadil showed twofold higher odds of 60-day survival in a secondary analysis of one 196-patient study, whose primary endpoint was not met, but the larger TESICO aviptadil comparison, with 471 randomized and 461 analyzed participants, found no statistically significant clinical benefit. The Shoemaker protocol has used VIP nasal spray in over 10,000 patients with mold illness, though this data comes from clinical practice rather than controlled trials.

Who researches VIP?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

Important considerations for

  • Those with Severe hypotension

    High

    VIP is a potent vasodilator. Can cause dangerous blood pressure drops.

  • Those with Diarrhea-predominant IBS

    Moderate

    VIP increases intestinal secretion and motility, potentially worsening diarrhea.

Safety & interactions

Do not use if

  • Severe hypotension

    High

    VIP is a potent vasodilator. Can cause dangerous blood pressure drops.

  • Diarrhea-predominant IBS

    Moderate

    VIP increases intestinal secretion and motility, potentially worsening diarrhea.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Hypotension and cardiovascular effects

    High

    PMID 37348524 (TESICO safety/monitoring); PMID 36044317

  • Very short plasma half-life (~2 minutes IV)

    High

    PMID 25595649 (NEP 24.11 inhibitor augments VIP aerosol effect); aviptadil continuous-infusion trial designs

  • Gastrointestinal side effects

    Moderate

    VIPoma/WDHA clinical literature; aviptadil trial safety reporting (PMID 37348524)

  • Limited long-term safety data from controlled trials

    High

    ClinicalTrials.gov aviptadil trial registry; PMID 20442436 (n=20, open-label)

  • Potential tumor-promoting effects in certain cancers

    Theoretical

    VPAC1 tumor-receptor imaging literature; in vitro proliferation studies

  • Pregnancy and lactation safety unknown

    Moderate

    Aviptadil trial exclusion criteria (ClinicalTrials.gov); absence of any human pregnancy exposure data

Interaction summary(8)

Rated by direction with this peptide

  • Antihypertensives (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers)

    CautionModerate

    Using VIP with any blood-pressure-lowering agent adds systemic vasodilation and hypotension. Hypotension is VIP's dose-limiting effect, and infusion protocols required blood-pressure monitoring for exactly this reason.

    Aviptadil infusion trial protocols (PMID 37348524); established VIP vasodilator pharmacology

  • Nitrates and other nitric-oxide donors

    CautionModerate

    Combined cAMP-mediated (VIP) and cGMP-mediated (nitrate) smooth-muscle relaxation can produce pronounced hypotension and reflex tachycardia.

    Mechanistic - convergent vasodilator pathways; no dedicated interaction study

  • PDE5 inhibitors (sildenafil, tadalafil)

    CautionModerate

    Genuine dual concern - additive vasodilation/hypotension risk systemically, while in PAH the cAMP (VIP) plus cGMP (PDE5i) combination is the rationale for potential pulmonary synergy; the interaction is real but unstudied in controlled trials.

    PAH combination-therapy rationale (PMID 18978135); mechanistic

  • Phentolamine (alpha-adrenergic blocker)

    SynergisticModerate

    The clinically exploited combination - aviptadil plus phentolamine is marketed in Europe as Invicorp for intracavernosal treatment of erectile dysfunction, confirming a real potentiating vasodilator interaction rather than a theoretical one.

    PMID 18485029; PMID 21050351 (Invicorp development history)

  • Neprilysin (NEP 24.11) inhibitors, e.g. sacubitril/valsartan

    SynergisticTheoretical

    NEP is a principal VIP-degrading enzyme, and co-application of a NEP inhibitor demonstrably augments and prolongs the pulmonary vasodilator effect of aerosolized VIP in preclinical models - potentially amplifying both benefit and hypotension in humans.

    PMID 25595649

  • Somatostatin analogs (octreotide, lanreotide)

    ProtectiveLow

    Octreotide opposes VIP signaling and is the standard treatment for VIPoma-associated secretory diarrhea, so it would be expected to blunt VIP-induced diarrhea and hypotension - and correspondingly to reduce any intended VIP effect.

    VIPoma/WDHA management literature

  • Corticosteroids

    SynergisticTheoretical

    Overlapping suppression of NF-kB-driven cytokine production suggests additive anti-inflammatory effect (both were used together in the COVID aviptadil trials as background therapy), but no interaction has been formally characterized and additive immunosuppression is the counterweight.

    PMID 37348524 (standard-of-care corticosteroid background in trial); mechanistic

  • Remdesivir

    NeutralLow

    Co-administered with IV aviptadil in the factorial TESICO trial without a reported pharmacologic interaction or excess toxicity attributable to the combination.

    PMID 37348524

Known risks(6)

  • Hypotension and cardiovascular effects

    Moderate to High (dose-dependent)

    VIP is a potent vasodilator that causes dose-dependent hypotension, particularly when administered intravenously. Compensatory tachycardia can occur. Transient facial flushing is common. IV administration requires hemodynamic monitoring. Nasal spray formulations produce milder systemic effects but hypotension remains a risk, especially in patients already on antihypertensive medications or with baseline low blood pressure.

  • Very short plasma half-life (~2 minutes IV)

    Moderate (pharmacokinetic limitation)

    VIP has an extremely short plasma half-life of approximately 2 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase. This necessitates continuous IV infusion for systemic effects or alternative delivery routes (nasal spray, inhalation) for sustained action. The rapid degradation limits bioavailability and may require multiple daily administrations.

  • Gastrointestinal side effects

    Low to Moderate

    VIP stimulates water and electrolyte secretion in the intestine. Side effects including diarrhea, nausea, and abdominal discomfort have been reported, particularly at higher doses. These are generally transient and dose-dependent. Patients with pre-existing secretory diarrhea conditions should use caution.

  • Limited long-term safety data from controlled trials

    Moderate (uncertainty)

    While over 10,000 patients have used VIP nasal spray in clinical practice since 2008, this data comes from observational clinical experience rather than randomized controlled trials. Long-term effects of chronic VIP administration on immune homeostasis, vascular function, and endocrine regulation have not been characterized through rigorous trials. The safety profile appears favorable based on available evidence, but the absence of large-scale RCT safety data represents an important gap.

  • Potential tumor-promoting effects in certain cancers

    Moderate (theoretical, requires monitoring)

    VIP and its receptors are overexpressed in certain tumors including VIPomas (rare pancreatic neuroendocrine tumors), breast cancer, prostate cancer, and some lung cancers. While VIP's role in cancer biology is complex (with both pro- and anti-tumorigenic effects reported), exogenous VIP administration should be approached cautiously in patients with active malignancies or a history of VIP-receptor-positive cancers.

  • Pregnancy and lactation safety unknown

    High (contraindicated due to insufficient data)

    No safety data exists for exogenous VIP use during pregnancy, lactation, or in children. Given VIP's broad physiological effects on vascular tone, immune regulation, circadian rhythms, and fetal neurodevelopment (VIP promotes embryonic neural growth), exogenous administration during pregnancy could have unpredictable effects. Contraindicated until safety data is available.

Drug interactions(6)

  • Antihypertensive medications (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers)

    VIP is a potent vasodilator. Concurrent use with antihypertensive medications may produce additive or synergistic hypotensive effects, increasing the risk of symptomatic hypotension, dizziness, and syncope. Blood pressure should be monitored closely when initiating VIP in patients on antihypertensive therapy, and dose adjustments may be necessary.

  • Nitrates and PDE5 inhibitors (nitroglycerin, sildenafil, tadalafil)

    VIP's vasodilatory mechanism via cAMP elevation can produce additive hypotension when combined with nitric oxide donors or PDE5 inhibitors, which also increase cyclic nucleotide levels. This combination carries a risk of severe hypotension. Concurrent use should be avoided or carefully monitored.

  • DPP-IV inhibitors (sitagliptin, saxagliptin, linagliptin)

    Dipeptidyl peptidase IV (DPP-IV) is a major enzyme responsible for VIP degradation. DPP-IV inhibitors (commonly used for type 2 diabetes) may prolong VIP's half-life and increase its bioavailability, potentially enhancing both therapeutic effects and side effects including hypotension and diarrhea. This interaction may actually be therapeutically advantageous but requires monitoring.

  • Immunosuppressant and immunomodulatory drugs (methotrexate, cyclosporine, biologics)

    VIP has potent immunomodulatory effects including generation of regulatory T cells, induction of tolerogenic dendritic cells, and suppression of Th1 inflammatory responses. Concurrent use with immunosuppressants could produce additive immunosuppression. Conversely, VIP's immune-reprogramming effects could theoretically interfere with the mechanism of certain biologics. Patients on immunomodulatory therapy should consult their physician.

  • Anticoagulants and antiplatelet agents

    VIP inhibits platelet aggregation and has vasodilatory effects. Concurrent use with anticoagulants (warfarin, heparin) or antiplatelet agents (aspirin, clopidogrel) may increase bleeding risk, though clinical significance is not well characterized. Monitoring is advised.

  • Corticosteroids (prednisone, dexamethasone)

    VIP is critical for circadian regulation of glucocorticoid secretion. Exogenous VIP administration in patients on corticosteroid therapy could alter the hypothalamic-pituitary-adrenal axis feedback. VIP's anti-inflammatory effects may be synergistic with corticosteroids but could also complicate dose management of steroid therapy.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
10000
Human Studies
15

VIP's clinical evidence base is paradoxically both extensive and incomplete. Preclinical evidence is among the strongest for any neuropeptide, with rigorous studies in Nature Medicine, JCI, Blood, and PNAS demonstrating potent immunomodulatory, neuroprotective, vasodilatory, and circadian regulatory effects. However, clinical translation has been limited. The pulmonary hypertension studies by Petkov et al. (2003) and Leuchte et al. (2008) showed clear benefits of inhaled VIP but remained small in scale. The COVID-19 ARDS trials yielded mixed results: Youssef et al. (2022, n=196) showed significant survival improvement, while the larger TESICO trial (2023; 471 randomized in the aviptadil comparison, 461 analyzed) was negative. The largest clinical experience comes from the Shoemaker CIRS protocol (10,000+ patients since 2008 using VIP nasal spray), which reports beneficial outcomes for biotoxin illness and chronic inflammation, but this evidence is observational and has not been validated through RCTs. Major gaps include the absence of large RCTs for autoimmune indications despite exceptional preclinical results, the absence of human neuroprotection trials and of randomized trials for the CIRS indication, and the short plasma half-life (~2 minutes IV), which presents formulation challenges for clinical development.

Researched for(6)

Rated by confidence in the evidence

  • Potent anti-inflammatory and immunomodulatory effects

    Medium

    Reduced inflammatory markers in a small human trial; extensive supporting animal data.

    PMID 20442436 (Prasse et al., Am J Respir Crit Care Med 2010, open-label phase II inhaled VIP in sarcoidosis)

  • Pulmonary vasodilation and treatment of pulmonary arterial hypertension

    Medium

    Inhaled VIP acutely lowers pulmonary vascular resistance in small human trials; long-term benefit unproven.

    PMID 18978135 (Leuchte et al., inhalation of VIP in pulmonary hypertension); PMID 25595649 (NEP-inhibitor coapplication study)

  • Neuroprotection against neurodegenerative disease

    Low

    Protects neurons in animal models via a clear mechanism; no human trials conducted.

    Preclinical VIP/PACAP neuroprotection literature; no registered human neurodegeneration trials on ClinicalTrials.gov

  • Circadian rhythm regulation and sleep quality

    Low

    Regulates circadian pacemaker neurons in animal studies; human sleep benefit unconfirmed.

    PMID 32636383 (VIP-VPAC2 pacemaking hub); PMID 11027354 (VPAC2 overexpression alters circadian phenotype); PMID 17572414 (review)

  • Gastrointestinal function and mucosal protection

    Low

    Established gut signaling role; animal data show protection, but high doses cause diarrhea.

    Enteric VIP physiology and VIPoma literature; rodent colitis models

  • Respiratory protection and treatment of ARDS

    Low

    Human RCTs in COVID respiratory failure did not confirm meaningful clinical benefit.

    PMID 37348524 (TESICO, IV aviptadil, placebo-controlled); PMID 36044317 (196-patient randomized COVID respiratory failure trial); PMID 39870064 (inhaled aviptadil randomized study)

Benefits(6)

  • Potent anti-inflammatory and immunomodulatory effects

    Delgado et al. 2001 (Nature Medicine, PMID 11329057) — VIP prevented experimental arthritis in mice by downregulating both autoimmune and inflammatory disease components, completely abrogating joint swelling and cartilage/bone destruction. Gonzalez-Rey et al. 2006 (Blood, PMC1895772) — VIP generates human tolerogenic dendritic cells that induce CD4+ and CD8+ regulatory T cells. VIP inhibits TNF-alpha, IL-6, and IL-12 production from macrophages and dendritic cells while promoting IL-10 secretion, shifting Th1/Th2 balance toward anti-inflammatory Th2 responses. Gonzalez-Rey & Delgado 2007 demonstrated VIP-generated Treg are therapeutic in collagen-induced arthritis and experimental autoimmune encephalomyelitis.

  • Pulmonary vasodilation and treatment of pulmonary arterial hypertension

    Petkov et al. 2003 (Journal of Clinical Investigation, PMID 12727925) — Inhaled VIP significantly improved exercise capacity and hemodynamics in patients with primary pulmonary hypertension over 24 weeks, with virtually no side effects. VIP was found to be deficient in serum and lung tissue of PAH patients. Leuchte et al. 2008 (European Respiratory Journal, PMID 18978135) — Single-dose inhaled VIP caused significant selective pulmonary vasodilation in 20 patients with pulmonary hypertension, with improved stroke volume and mixed venous oxygen saturation. Said et al. 2007 (PMID 19076374) — VIP gene knockout mice develop moderate pulmonary arterial hypertension with vascular remodeling.

  • Neuroprotection against neurodegenerative disease

    Gozes et al. 2000 (Brain Research, PMID 10784133) — VIP prevented neurotoxicity in neuronal cultures relevant to Parkinson's disease. VIP neuroprotection is mediated by femtomolar-acting glial proteins including activity-dependent neurotrophic factor (ADNF) and activity-dependent neuroprotective protein (ADNP). Brenneman et al. 2003 (PMID 14501014) — From VIP through ADNP to the NAP neuroprotective peptide, established the VIP-driven neuroprotective cascade. Dejda et al. 2005 (PMID 15872042) — VIP neuroprotection against neonatal excitotoxic brain lesions is mediated via VPAC2 receptors. Rangon et al. 2006 (PMID 20632962) — Review of therapeutic potential of VIP and receptors in Alzheimer's, Parkinson's, and autism.

  • Circadian rhythm regulation and sleep quality

    Colwell et al. 2003 (PMID 14557231) — VIP is a crucial component of circadian timekeeping machinery, acting as a major synchronizing agent among SCN neurons. Aton et al. 2005 (Nature Neuroscience, PMID 17572414) — VIP is essential for maintaining circadian rhythms in the mammalian SCN. Vosko et al. 2007 (PMID 18562786) — VIP is critical for circadian regulation of glucocorticoids. Colwell et al. 2010 (PMC3001794) — VIP-deficient mice show decreased REM sleep and altered circadian sleep regulation, with disrupted rhythms in gene expression in the SCN.

  • Gastrointestinal function and mucosal protection

    Vu et al. 2019 (Frontiers in Physiology, PMC6743256) — Comprehensive review of VIP's roles in the GI system including regulation of ion secretion, nutrient absorption, gut motility, glycemic control, and mucosal immune responses. VIP knockout mice show increased villus length, reduced mucus secretion, thickened muscle layers, and impaired GI transit. VIP stimulates electrolyte and water secretion in the intestine and acts as an inhibitory non-adrenergic, non-cholinergic neurotransmitter regulating smooth muscle relaxation.

  • Respiratory protection and treatment of ARDS

    Youssef et al. 2022 (Critical Care Medicine, PMID 36044317) — IV Aviptadil showed significant two-fold improvement in 60-day survival (OR 2.0, p=0.035) in 196 patients with COVID-19 respiratory failure, with significant reduction in IL-6 by day 3. Patients on mechanical ventilation experienced 10-fold increased odds of survival with Aviptadil versus placebo (p=0.031). However, the larger TESICO trial (PMID 37348524, n=530) did not confirm these findings.

Key studies(5)

  1. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

    Preclinical experimental studyMouse model of collagen-induced arthritisTreatment during disease induction and progression

    Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP

    Nature Medicine

    2001

    Landmark study establishing VIP as a potent immunomodulatory peptide. Daily VIP administration significantly reduced both the incidence and severity of collagen-induced arthritis in mice, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect was mediated by downregulation of both autoimmune (Th1 cytokines, autoantibodies) and inflammatory (TNF-alpha, IL-6, chemokines) disease components. This paper opened the field of VIP-based immunotherapy for autoimmune diseases.

  2. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

    Clinical proof-of-concept studyPatients with primary pulmonary hypertension24 weeks of inhaled VIP (200 mcg/day)

    Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH

    Journal of Clinical Investigation

    2003

    Demonstrated that VIP is deficient in serum and lung tissue of patients with primary pulmonary hypertension. Inhaled VIP (200 mcg/day) significantly improved exercise capacity compared with baseline at 12 weeks (P<0.01) and further improved at 24 weeks (P<0.01). Virtually no side effects were observed. Established VIP inhalation as a novel therapeutic approach for PAH with selective pulmonary vasodilatory effects.

  3. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

    Multicenter randomized controlled trial (Phase 2b/3)196 patients (2:1 randomization, Aviptadil vs placebo)3 days IV infusion, 60-day follow-up

    Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, Perez Fernandez J, Morganroth ML, Javitt JC, Jayaweera D

    Critical Care Medicine

    2022

    Primary endpoint (alive and free from respiratory failure at day 60) did not reach statistical significance (OR 1.6, 95% CI 0.86-3.11). However, there was a statistically significant two-fold improvement in 60-day survival (OR 2.0, 95% CI 1.1-3.9, p=0.035). Significant reduction in IL-6 by day 3 (p=0.02). Patients on mechanical ventilation experienced 10-fold increased odds of survival with Aviptadil versus placebo (p=0.031). Demonstrated biological plausibility but primary endpoint was not met.

  4. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

    Multicenter randomized placebo-controlled trial471 randomized in the aviptadil comparison; 461 received study infusion and entered the modified intention-to-treat analysis.3 days IV infusion, 90-day follow-up

    ACTIV-3b/TESICO Study Group

    Lancet Respiratory Medicine

    2023

    Aviptadil did not improve the primary endpoint of recovery status at day 90, nor did it improve mortality at 90 days or any other study endpoint in patients with COVID-19 acute hypoxaemic respiratory failure. This large, well-powered negative trial tempered enthusiasm for VIP-based ARDS therapy and confirmed the high mortality experienced by COVID-19 patients with acute hypoxaemic respiratory failure under current standard of care.

  5. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells

    Preclinical immunology studyIn vitro human cell studies and in vivo mouse modelsN/A (mechanistic study)

    Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M

    Blood

    2006

    Demonstrated that VIP induces the generation of human tolerogenic dendritic cells from monocyte-derived DCs, which in turn induce both CD4+ and CD8+ regulatory T cells. These VIP-generated Treg showed therapeutic efficacy in collagen-induced arthritis and experimental autoimmune encephalomyelitis mouse models, and in graft-versus-host disease prevention. Established a novel immunosuppressive mechanism from neuropeptides to regulatory T cells with translational potential for autoimmune disease therapy.

Regulation & availability

Why researchers look at it

Over 10,000 published studies document roles spanning inflammation, neuroprotection, vascular tone, gut integrity, and circadian regulation — few molecules touch as many aging-relevant systems. Real-world data from the Shoemaker protocol (10,000+ patients since 2008) provides extensive safety evidence, though controlled COVID-19 trials yielded mixed results. If better delivery methods can harness its broad anti-inflammatory and neuroprotective properties, VIP could address multiple hallmarks of aging simultaneously.

Estimated cost
$150-400/mo compounding (nasal spray)
FDA status
VIP is not FDA-approved as a finished pharmaceutical product. Vasoactive intestinal peptide remains in Category 1 on FDA's May 14, 2026 interim 503A list, with conditional enforcement discretion while FDA evaluates the substance, so pharmacies may compound it for an individual patient's prescription. Category 1 placement does not establish safety, efficacy, or compliance with every compounding requirement, and compounded VIP has not been reviewed by FDA for safety or effectiveness. The synthetic form aviptadil (brand name Zyesami) was developed by NRx Pharmaceuticals (formerly NeuroRx) and Relief Therapeutics for COVID-19 ARDS and remains investigational.
WADA status
VIP/aviptadil is not individually named on the 2026 WADA Prohibited List. Aviptadil is an ingredient in authorized aviptadil/phentolamine medicines, so worldwide nonapproval cannot be assumed when assessing S0. Peptide identity alone does not establish an S2 prohibition. Athletes should obtain a product- and route-specific determination from their anti-doping organization.
Prescribability
VIP may be compounded under FDA's conditional 503A Category 1 interim enforcement policy when all applicable conditions are met, including a valid patient-specific prescription. Compounded VIP is not FDA-approved and has not been reviewed by FDA for safety or effectiveness.
Availability
VIP availability varies by formulation and jurisdiction. In the United States, licensed 503A compounding pharmacies prepare VIP nasal spray for patient-specific prescriptions. VIP is in Category 1 on FDA's interim 503A bulk drug substances list, which allows compounding under conditional enforcement discretion while FDA continues its evaluation. Over 10,000 patients have been treated with compounded VIP nasal spray since 2008, primarily through Shoemaker-protocol CIRS practitioners. The synthetic VIP product aviptadil (Zyesami) is available only through clinical trials and is not FDA-approved. Internationally, aviptadil is an ingredient in nationally authorized aviptadil/phentolamine injection products, including Invicorp, for erectile dysfunction. These authorizations do not cover VIP nasal spray or CIRS. Compounded formulations may be available through functional medicine and integrative health practitioners in some jurisdictions. The regulatory status of compounded VIP remains subject to change as FDA completes its review of peptide bulk drug substances.

International status

  • EU

    Aviptadil/phentolamine products have national authorizations in several European countries for erectile dysfunction; these do not authorize VIP nasal spray or CIRS treatment.

  • US

    VIP is not FDA-approved. FDA is evaluating it for its list of bulk substances pharmacies may use (Category 1), and in the meantime pharmacies may compound it for an individual patient's prescription. Compounded VIP has not been reviewed by FDA for safety or effectiveness.

  • Worldwide

    Aviptadil is approved as an ingredient in combination medicines for erectile dysfunction in some jurisdictions; approval is formulation- and indication-specific.

Regulatory timeline(15)

  1. 1970
    VIP isolated from porcine small intestine by Sami I. Said and Viktor Mutt. Published in Science (169:1217-1218). Named for its potent vasodilatory activity.
  2. 1972
    Said and Mutt publish full characterization of VIP as a 28-amino-acid octacosapeptide related to secretin and glucagon (European Journal of Biochemistry 28:199-204).
  3. 1970s-1980s
    VIP established as a neurotransmitter/neuromodulator distributed throughout the CNS, PNS, and gut. Receptors (later named VPAC1 and VPAC2) characterized.
  4. 2001
    Delgado et al. publish landmark study in Nature Medicine demonstrating VIP prevents experimental arthritis, establishing VIP as a major immunomodulatory peptide (PMID 11329057).
  5. 2003
    Petkov et al. publish proof-of-concept study in Journal of Clinical Investigation showing inhaled VIP improves pulmonary arterial hypertension (PMID 12727925).
  6. 2005-2006
    Gonzalez-Rey, Chorny, and Delgado demonstrate VIP induces tolerogenic dendritic cells and regulatory T cells (PNAS 2005, Blood 2006).
  7. 2008
    Dr. Ritchie Shoemaker begins prescribing VIP nasal spray as final step in CIRS protocol. Leuchte et al. publish inhaled VIP hemodynamic data in pulmonary hypertension (Eur Respir J).
  8. 2020-03
    NRx Pharmaceuticals files IND for Aviptadil (RLF-100) in COVID-19. FDA issues 'Study May Proceed' letter within 4 days (March 28, 2020).
  9. 2020-06
    FDA grants Fast Track Designation to Aviptadil for critical COVID-19 with respiratory failure.
  10. 2020-09
    NRx submits first request for Emergency Use Authorization (EUA) for Aviptadil to the FDA.
  11. 2021-11-04
    FDA declines first EUA for Zyesami (aviptadil), citing insufficient data regarding known and potential benefits and risks in patients with critical COVID-19.
  12. 2022-07-01
    FDA declines second EUA for Zyesami for a subgroup of patients with critical COVID-19 also receiving remdesivir.
  13. 2022-11
    Youssef et al. publish phase 2b/3 RCT results in Critical Care Medicine: IV Aviptadil shows survival benefit but misses primary endpoint (PMID 36044317).
  14. 2023-09
    TESICO trial published in Lancet Respiratory Medicine: negative trial (471 randomized in the aviptadil comparison; 461 analyzed) finds Aviptadil does not improve recovery or mortality in COVID-19 ARDS (PMID 37348524).
  15. 2024-2025
    VIP remains under Category 1 on FDA interim bulk drug substances list. FDA considers but does not remove VIP from compounding list. ISEAI and practitioners advocate to preserve compounding access.

Sources & FAQs

Research sources(18)

Frequently asked questions(5)

What is VIP primarily used for in clinical practice?

In current clinical practice, VIP is most commonly prescribed as a nasal spray as the final step in Dr. Ritchie Shoemaker's 11-step protocol for treating Chronic Inflammatory Response Syndrome (CIRS), a multi-system illness caused by exposure to water-damaged buildings and biotoxins. VIP is also being explored by functional medicine practitioners for broader inflammatory, neurodegenerative, and pulmonary conditions. The synthetic form Aviptadil has been studied in clinical trials for pulmonary arterial hypertension and COVID-19 ARDS, though it has not received FDA approval.

How does VIP differ from other anti-inflammatory peptides?

VIP is unique among anti-inflammatory peptides because it operates at the intersection of the nervous and immune systems. While many anti-inflammatory agents suppress immune responses broadly, VIP generates tolerogenic dendritic cells and regulatory T cells, essentially reprogramming the immune system toward tolerance rather than simply suppressing it. VIP also simultaneously regulates circadian rhythms, pulmonary vascular tone, gastrointestinal function, and neuronal survival — a breadth of action unmatched by most peptide therapies. Its short plasma half-life (~2 minutes IV) is a significant limitation, which is why nasal spray and inhaled formulations are preferred for clinical use.

Is VIP safe? What are the main side effects?

VIP has a generally favorable safety profile based on extensive clinical use. In the Shoemaker CIRS protocol, over 10,000 patients have used VIP nasal spray since 2008 with an impeccable reported safety record. Common side effects are mild and include transient facial flushing, nasal irritation, occasional diarrhea, and mild hypotension due to its vasodilatory properties. When administered intravenously (as Aviptadil), dose-dependent hypotension and compensatory tachycardia are the primary concerns, requiring hemodynamic monitoring. Nausea, dizziness, and headache have also been reported. The main safety limitation is that long-term randomized controlled trial data is limited.

Can VIP help with mold illness or biotoxin exposure?

VIP nasal spray is the cornerstone of the final step in Dr. Shoemaker's CIRS protocol for patients with mold-related biotoxin illness. Clinical experience from over 10,000 patients suggests VIP can help normalize inflammatory biomarkers (such as C4a, TGF-beta1, VEGF, and MMP-9), support healthy hormone levels, reduce systemic inflammation, regulate immune function, and aid brain healing in CIRS patients. However, this evidence comes from clinical practice observations and published case series rather than randomized controlled trials, and the CIRS diagnosis and protocol remain controversial in mainstream medicine.

Does VIP have anti-aging or longevity benefits?

No direct lifespan extension studies have been conducted with VIP. However, VIP has multiple properties highly relevant to aging biology: (1) it is the primary circadian synchronizer in the suprachiasmatic nucleus, and circadian disruption is a hallmark of aging; (2) it potently inhibits pro-inflammatory cytokines that drive inflammaging; (3) it induces neuroprotective factors (ADNP, ADNF) that protect against age-related neurodegeneration; (4) it promotes REM sleep, which declines with age and is critical for cognitive maintenance; (5) it maintains gastrointestinal and pulmonary function. VIP-deficient mice show accelerated features of aging including circadian disruption, reduced REM sleep, and GI dysfunction. These properties position VIP as a candidate for healthspan extension rather than a proven longevity agent.